All News

Gout.T2T.jpg

Treat-to-Target Works in Gout With No Cardiac Toxicity

d ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of patients reaching target urate levels. Additionally, both appeared safe, with no evidence of increased cardiovascular toxicity (Abstract #1900).

Read Article
exhibitor.floor.ACR

Industry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca

d Jack Cush, MD

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to review and look for in the meeting.

Read Article
Telemedicine black computer

Negative Concerns of Telemedicine in Rheumatology

d Jack Cush, MD

Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.

Read Article
test-214244__180.jpg (keep)

NOR-DRUM Study: TNF Inhibitor Therapeutic Drug Monitoring is Effective

d ACR

New research presented this week at ACR  Convergence, the American College of  Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a patient’s drug serum levels are regularly assessed to adjust the dose and intervals, controlled disease more effectively than standard therapy with infliximab, a tumor necrosis factor (TNF) inhibitor.   

Read Article
URI.infection.COrona.jpg

Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased

d ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

Read Article
New Download Available! The Scary Side of Steroid. Log in to RheumNow to download. https://t.co/0OfMAsFvWu https://t.co/FpT4aqV8pV

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Scary Steroids QD Clinic is sponsored by https://t.co/V10S4oVFsv's coverage of #ACR21 https://t.co/jnruS0m3Gr https://t.co/REMKWoR6DQ

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 is just days away and we want to see your best images of learning virtually, missing a meeting in San Francisco, wellness, or break time activities. Tweet your pic and make sure to include #RheumPix and #ACR21 and we’ll share our favorites. https://t.co/DTyOKrlG7J
Dr. John Cush RheumNow ( View Tweet)
Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased #ACR21 https://t.co/dWrlIBHya7 https://t.co/U9hXcXUrI5

Links:

Dr. John Cush RheumNow ( View Tweet)
NOR-DRUM Study: TNF Inhibitor Therapeutic Drug Monitoring is Effective https://t.co/RPS6OiXsx2 #ACR21 https://t.co/uMv5LNq3Sh

Links:

Dr. John Cush RheumNow ( View Tweet)
Sign up today to receive #ACR21 news and select topic emails throughout the conference. #RheumNow https://t.co/riyAnrRHhX https://t.co/IEjvmn7glF

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose This abstract will be presented at 10:45am EST, Tuesday, November 9, 2021 during the Late-Breaking Abstracts session (L16 - L21). #ACR21 https://t.co/A1nAL8OnCu https://t.co/lsSyZmjfuF

Links:

Dr. John Cush RheumNow ( View Tweet)
#ClinicalPearl Distal fingers in #Scleroderma lose pulp. In this patient #calcinosis (chronic) caused the nail/bed to expand! @RheumNow @CRASCRRheum https://t.co/bj4cxP7q6J
Janet Pope Janetbirdope ( View Tweet)
I like this. Downloaded and read. Great for patients too! https://t.co/B081u0ijjU

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey of 10,234 Dannish Primary Care pts (w/ LBP, hip or knee #OA)to Dx self reported Lumbar Spinal Stenosis (LSS) based on 11 Sxs. LSS Sxs were more in LBP (11–71%) than hip (11–50%) or knee OA (8–40%). Overall LSS seen <10% cohorts https://t.co/v9LO09IZla

Links:

Dr. John Cush RheumNow ( View Tweet)

But baricitinib inhibits endocytosis of the virus and thus should be antiviral early in the disease. I believe the paradox is based on who gets bari, mostly those with poorly controlled disease https://t.co/euOthMLDt3

Links:

Dr. John Cush RheumNow ( View Tweet)

1119 thoracic aortic surgeries - 3.7% dx as inflammatory aortitis (66% CIA, 27% GCA, 5% TAK) (20% given steroids). Aortitis were more female, older, more HTN w/ more immunosuppressives, but no diff in 30d mortality (7.3 vs 6.5%) https://t.co/94VBaRAry5

Links:

Dr. John Cush RheumNow ( View Tweet)

Happy Diwali to all my Twitter friends. May this festival of light glow your life with knowledge, happiness and prosperity. I also feel for all those who lost their loved one this year to Covid and may Diwali brings peace to you as well. https://t.co/xRGnuxz068
Rohit Aggarwal docrota ( View Tweet)
CRESPA trial pts (Golimumab in monoRx peripheral SpA) offered change to MTX. 25/60 pSpA entered the step-down to MTX, but 21/25 flared & 4 (16%) stayed in remission (others restarted GOL). MTX cant maintain GOL remission in pSpA https://t.co/zGg3UqoDqp

Links:

Dr. John Cush RheumNow ( View Tweet)

Drug development in the USA: Did you know? 1. Typical drug development timeline is 10-15 years; 2. It cost as much as US $2.6 billion to bring a drug to market; 3. Only 0.02% of drugs in development make it to market https://t.co/GXKddBLOUv

Links:

Dr. John Cush RheumNow ( View Tweet)

×